Membrane cholesterol content influences binding properties of muscarinic M2 receptors and differentially impacts activation of second messenger pathways.
We investigated the influence of membrane cholesterol content on preferential and non-preferential signaling through the M(2) muscarinic acetylcholine receptor expressed in CHO cells. Cholesterol depletion by 39% significantly decreased the affinity of M(2) receptors for [(3)H]-N-methylscopolamine ([(3)H]-NMS) binding and increased B(max) in intact cells and membranes. Membranes displayed two-affinity agonist binding sites for carbachol and cholesterol depletion doubled the fraction of high-affinity binding sites. In intact cells it also reduced the rate of agonist-induced receptor internalization and changed the profile of agonist binding from a single site to two affinity states. Cholesterol enrichment by 137% had no effects on carbachol E(max) of cAMP synthesis inhibition and on cAMP synthesis stimulation and inositolphosphates (IP) accumulation at higher agonist concentrations (non-preferred pathways). On the other hand, cholesterol depletion significantly increased E(max) of cAMP synthesis inhibition or stimulation without change in potency, and decreased E(max) of IP accumulation. Noteworthy, modifications of membrane cholesterol had no effect on membrane permeability, oxidative activity, protein content, or relative expression of G(s), G(i/o), and G(q/11) alpha subunits. These results demonstrate distinct changes of M(2) receptor signaling through both preferential and non-preferential G-proteins consequent to membrane cholesterol depletion that occur at the level of receptor/G-protein/effector protein interactions in the cell membrane. The significant decrease of IP accumulation by cholesterol depletion was also observed in cells expressing M(3) receptors and by both cholesterol depletion and enrichment in cells expressing M(1) receptors indicating relevance of reduced G(q/11) signaling for the pathogenesis of Alzheimer's disease.
Institute of Physiology CAS, Prague, Czech Republic.
Pavel
P
Michal
Vladimír
V
Rudajev
Esam E
EE
El-Fakahany
Vladimír
V
Dolezal
D000109:Acetylcholine / Q000031:analogs & derivatives; D000818:Animals; D016466:CHO Cells; D002217:Carbachol / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism*; D006224:Cricetinae; D003412:Cricetulus; D019204:GTP-Binding Proteins / Q000378:metabolism; D006801:Humans; D018727:Muscarinic Antagonists / Q000494:pharmacology; D019832:N-Methylscopolamine / Q000378:metabolism / Q000494:pharmacology; D043585:Receptor, Muscarinic M2 / Q000378:metabolism*; D015290:Second Messenger Systems / Q000187:drug effects; D047392:beta-Cyclodextrins / Q000494:pharmacology
D018727:Muscarinic Antagonists; D043585:Receptor, Muscarinic M2; D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin; D002217:Carbachol; D002784:Cholesterol; D019204:GTP-Binding Proteins; D000109:Acetylcholine; D019832:N-Methylscopolamine